Navigation Links
Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
Date:1/28/2008

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that in a special meeting today shareholders approved the proxy proposal amending and restating the Company's articles of incorporation to increase the number of authorized shares from 110 million to 210 million and to increase the number of authorized shares of common stock from 100 million to 200 million.

Louis A. Bianco, Chief Financial Officer at CTI, who chaired the meeting, said "The increase in the number of authorized shares of common stock provides CTI with flexibility needed to support the future growth of the business. I'd like to thank all of the shareholders who returned their proxies."

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include risks related to the impact of the increase in authorized shares of stock and the future business growth of the Company as well as the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
3. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
6. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
7. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
8. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
9. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
10. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... and Brent Butler 2 , ... Massachusetts, USA , ... , Introduction , ... carried out using manual pipetting. As the demand for greater throughput of plate ...
... , , , , FLEXSTATION IS A ... SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS , , ... , EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR ... G q -coupled receptors are transmembrane proteins that are responsible ...
... , HOMOGENEOUS ASSAY , , ... PROCEDURE , , COMPATIBLE WITH MORE TARGETS ... , The ... detecting changes,in intracellular calcium concentration.,Specifically, this fast and simple fluorescencebased,assay allows the ...
Cached Biology Technology:96 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 296 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 4Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 2Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 3Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 4Calcium Plus Assay Kit, Superior Detection for Specialized Targets 2Calcium Plus Assay Kit, Superior Detection for Specialized Targets 3
(Date:4/23/2014)... of Public Health-Bloomington has bolstered the link between red ... association between heme iron, found only in meat, and ... that heme iron consumption increased the risk for coronary ... found between nonheme iron, which is in plant and ... study was published online ahead of print in the ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... the likelihood of an accurate group decision increases with ... when a collective faces a variety of factors ... University researchers report that smaller groups actually tend to ... excessively focused on only certain pieces of information. , ... known about collective intelligence, or the "wisdom of crowds," ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... Va. The availability of new genome sequencing ... to test an intriguing hypothesis about how agricultures ... plant pathogens. Boris Vinatzer, assistant professor of ... College of Agriculture and Life Sciences, has received ...
... GAINESVILLE, Fla. Using the genetic equivalent of an ... the Earth endured a massive cooling period between 500 ... (Feb. 7) in the journal Nature, researchers from the ... and the biotechnology company DNA2.0 describe how they reconstructed ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Scientists rebuild ancient proteins to reveal primordial Earth's temperature 2Madagascar's tortoises are crawling toward extinction, groups say 2
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Biology Products: